Efficacy of clarithromycin in the adjuvant treatment of chronic periodontitis: a Meta-analysis

doi:10.7518/hxkq.2020.03.011

Abstract

Abstract:

Objective To evaluate the clinical efficacy of clarithromycin (CLM) in the adjuvant treatment of chronic periodontitis systematically, obtain reasonable conclusions through evidence-based medicine, and provide guidance for clinical rational drug use. Methods Literature about CLM in the adjuvant treatment of chronic periodontitis was searched in CNKI, VIP, Wanfang, Chinese Biomedical Literature Database, PubMed, ScienceDirect, and Embase databases from inception to February 2019 using a computer. Meta-analysis was performed on the homogeneous study using RevMan 5.3 software after two independent reviewers screened the literature, evaluated the quality of the study, extracted the data, and evaluated the risk of bias in the included studies. Results Six randomized controlled trials were included in 316 subjects. The meta-analysis showed that compared with the scaling and root planning (SRP) group, the probing depth (PD) was reduced in patients with CLM and SRP [MD=-1.00, 95%CI (-1.55, -0.45), P=0.000 04]. Clinical attachment loss was obtained [MD=-0.03, 95%CI (0.43, 0.65), P<0.000 01], and the difference between the groups was statistically significant. The modified sulcus bleeding index (mSBI) was reduced [MD=-0.01, 95%CI (-0.14, 0.19), P=0.66]. No significant difference was observed between the groups, but the decrease in mSBI was more significant in CLM combined with SRP group. Conclusion CLM combined with subgingival SRP can achieve remarkable results in treating chronic periodontitist.

Key words: clarithromycin, non-surgical periodontal therapy, chronic periodontitis, Meta-analysis

CLC Number:

R781.4

Bai Yin, Bai Yuanliang, Lai Jing, Huang Jiao. Efficacy of clarithromycin in the adjuvant treatment of chronic periodontitis: a Meta-analysis[J]. West China Journal of Stomatology, 2020, 38(3): 290-296.

Figures/Tables 6

Fig 1

Tab 1

Tab 2

Fig 2

Fig 3

Fig 4

References 27

[1]	Miani PK, do Nascimento C, Sato S , et al. In vivo evaluation of a metronidazole-containing gel for the adjuvant treatment of chronic periodontitis: preliminary results[J]. Eur J Clin Microbiol Infect Dis, 2012,31(7):1611-1618.
[2]	Ribeiro Edel P, Bittencourt S, Zanin IC , et al. Full-mouth ultrasonic debridement associated with amoxicillin and metronidazole in the treatment of severe chronic periodontitis[J]. J Periodontol, 2009,80(8):1254-1264. doi: 10.1902/jop.2009.080403 URL
[3]	Lindhe J, Nyman S . The effect of plaque control and surgical pocket elimination on the establishment and maintenance of periodontal health. A longitudinal study of periodontal therapy in cases of advanced disease[J]. J Clin Periodontol, 1975,2(2):67-79. doi: 10.1111/cpe.1975.2.issue-2 URL
[4]	Rabbani GM, Ash MM Jr, Caffesse RG . The effectiveness of subgingival scaling and root planing in Calculus removal[J]. J Periodontol, 1981,52(3):119-123.
[5]	Stambaugh RV, Dragoo M, Smith DM , et al. The limits of subgingival scaling[J]. Int J Periodontics Restorative Dent, 1981,1(5):30-41.
[6]	Goodson JM . Antimicrobial strategies for treatment of periodontal diseases[J]. Periodontol 2000, 1994,5:142-168.
[7]	Haffajee AD, Socransky SS, Gunsolley JC . Systemic anti-infective periodontal therapy. A systematic review[J]. Ann Periodontol, 2003,8(1):115-181. doi: 10.1902/annals.2003.8.1.115 URL
[8]	Beikler T, Prior K, Ehmke B , et al. Specific antibiotics in the treatment of periodontitis: a proposed strategy[J]. J Periodontol, 2004,75(1):169-175.
[9]	Slots J , Research, Science and Therapy Committee. Systemic antibiotics in periodontics[J]. J Periodontol, 2004,75(11):1553-1565. doi: 10.1902/jop.2004.75.11.1553 URL
[10]	Moore PA . Dental therapeutic indications for the newer long-acting macrolide antibiotics[J]. J Am Dent Assoc, 1999,130(9):1341-1343. doi: 10.14219/jada.archive.1999.0404 URL
[11]	李德懿, 顾晶晶, 章程 , 等. 牙周微生态与龈沟液pH关系初探[J]. 中国微生态学杂志, 1999,11(4):225-226.
	Li DY, Gu JJ, Zhang C , et al. Preliminary study on the relationship of periodontal microecosysem to pH in gingival crevicular fluid[J]. Chin J Microecol, 1999,11(4):225-226.
[12]	MacLeod CM, Hamid QA, Cameron L , et al. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa[J]. Adv Ther, 2001,18(2):75-82. doi: 10.1007/BF02852391 URL
[13]	Jang YJ . Effect of clarithromycin on rhinovirus-16 infection in A549 cells[J]. Eur Respir J, 2006,27(1):12-19.
[14]	Bosnar M, Bosnjak B, Cuzic S , et al. Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta[J]. J Pharmacol Exp Ther, 2009,331(1):104-113.
[15]	Peric A, Vojvodic D, Baletic N , et al. Influence of allergy on the immunomodulatory and clinical effects of long-term low-dose macrolide treatment of nasal polyposis[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2010,154(4):327-333.
[16]	Arora A, Dodwad V, Vaish S , et al. Clinical efficacy of subgingivally delivered 0.5% controlled release clarithromycin gel in the management of chronic periodontitis[J]. J Pierre Fauchard Acad India Sect, 2014,28(2):68-72.
[17]	Andere NMRB, Castro Dos Santos NC, Araujo CF , et al. Clarithromycin as an adjunct to one-stage full-mouth ultrasonic periodontal debridement in generalized aggressive periodontitis: a randomized controlled clinical trial[J]. J Periodontol, 2017,88(12):1244-1252. doi: 10.1902/jop.2017.170165 URL
[18]	Bajaj P, Pradeep AR, Agarwal E , et al. Locally delivered 0.5% clarithromycin, as an adjunct to nonsurgical treatment in chronic periodontitis with well-controlled type 2 diabetes: a randomized controlled clinical trial[J]. J Investig Clin Dent, 2012,3(4):276-283.
[19]	Agarwal E, Pradeep AR, Bajaj P , et al. Efficacy of local drug delivery of 0.5% clarithromycin gel as an adjunct to non-surgical periodontal therapy in the treatment of current smokers with chronic periodontitis: a randomized controlled clinical trial[J]. J Periodontol, 2012,83(9):1155-1163.
[20]	Kathariya R, Pradeep AR, Raghavendra NM , et al. Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial[J]. J Investig Clin Dent, 2014,5(1):23-31.
[21]	Pradeep AR, Kathariya R . Clarithromycin, as an adjunct to non surgical periodontal therapy for chronic periodontitis: a double blinded, placebo controlled, randomized clinical trial[J]. Arch Oral Biol, 2011,56(10):1112-1119.
[22]	Haas AN, de Castro GD, Moreno T , et al. Azithromycin as an adjunctive treatment of aggressive periodontitis: 12-months randomized clinical trial[J]. J Clin Periodontol, 2008,35(8):696-704. doi: 10.1111/cpe.2008.35.issue-8 URL
[23]	Moher D, Hopewell S, Schulz KF , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials[J]. Int J Surg, 2012,10(1):28-55. doi: 10.1016/j.ijsu.2011.10.001 URL
[24]	Varela VM, Heller D, Silva-Senem MX , et al. Systemic antimicrobials adjunctive to a repeated mechanical and antiseptic therapy for aggressive periodontitis: a 6-month randomized controlled trial[J]. J Periodontol, 2011,82(8):1121-1130.
[25]	Chou CH, Walters JD . Clarithromycin transport by gingival fibroblasts and epithelial cells[J]. J Dent Res, 2008,87(8):777-781. doi: 10.1177/154405910808700812 URL
[26]	Burrell RC, Walters JD . Distribution of systemic clarithromycin to gingiva[J]. J Periodontol, 2008,79(9):1712-1718.
[27]	Goldstein EJ, Citron DM, Merriam CV , et al. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes[J]. Antimicrob Agents Chemother, 1999,43(11):2801-2805.

纳入研究	例数（T/C）	年龄/岁	干预措施		随访时间/月	纳入时PD/mm	主要结局指标
纳入研究	例数（T/C）	年龄/岁	T	C	随访时间/月	纳入时PD/mm	主要结局指标
Arora等^[16]	15/15	25~40	CLM+SRP	SRP	1	≥4	PD、CAL、PI、GI
Andere等^[17]	20/20	<35	CLM+SRP	SRP	6	>5	PD、CAL、BOP、FMPI
Bajaj等^[18]	29/27	30~50	CLM+SRP	SRP	6	≥5	PD、PAL、PI、GI、mSBI
Agarwal等^[19]	28/27	30~50	CLM+SRP	SRP	6	≥5	PD、CAL、PI、GI、mSBI
Kathariya等^[20]	50/48	25~50	CLM+SRP	SRP	3	≥5	PD、PAL、PI、GI、mSBI
Pradeep等^[21]	18/19	25~50	CLM+SRP	SRP	9	≥5	PD、CAL、GI

纳入研究	随机分组方法	分配隐藏	盲法	不完整结果数据	选择性报告结果	其他偏倚
Arora等^[16]	不清楚	是	双盲	否	否	不清楚
Andere等^[17]	随机数字	是	双盲	否	否	不清楚
Bajaj等^[18]	随机数字	是	双盲	否	否	不清楚
Agarwal等^[19]	随机数字	是	双盲	否	否	不清楚
Kathariya等^[20]	随机数字	是	双盲	否	否	不清楚
Pradeep等^[21]	随机数字	是	双盲	否	否	不清楚